Preoperative use of narcotics for pain management ([@b1-prm-20-129]) and soft tissue dissection in posterior spine surgery ([@b2-prm-20-129],[@b3-prm-20-129]) lead to significant postoperative pain. Increased demand for spine surgery, and emphasis on patient-centred care and reduced length of stay in hospital, has led to a search for better methods of postoperative pain management. Intrathecal administration of opioids for acute and severe pain relief in humans was first reported by Wang et al ([@b4-prm-20-129]) in 1979. Morphine was the first to receive United States Food and Drug Administration approval for epidural and intrathecal use, and remains the most widely investigated and extensively used spinal opioid for postoperative analgesia. There are reports regarding the analgesic efficacy of intrathecal morphine (ITM) ([@b4-prm-20-129]--[@b7-prm-20-129]) as well as concerns about its use ([@b8-prm-20-129]). The reported high incidence of respiratory depression and somnolence ([@b9-prm-20-129]) led Etches et al ([@b10-prm-20-129]) to state that until the effect on outcome, morbidity and mortality are known, the value of spinal opioids for the management of postoperative pain is unproven. Others believe that the risk for respiratory depression and somnolence was related to the high opioid doses used, and lowering opioid doses has been advocated ([@b5-prm-20-129],[@b11-prm-20-129],[@b12-prm-20-129]). ITM ≤0.1 mg has been shown to be an effective, convenient and simple method for managing postoperative pain after Caesarean section ([@b5-prm-20-129],[@b13-prm-20-129],[@b14-prm-20-129]) and cholecystectomy ([@b15-prm-20-129]). Other operations, such as cardiac ([@b16-prm-20-129]), orthopedic ([@b6-prm-20-129],[@b11-prm-20-129],[@b17-prm-20-129]), hysterectomy ([@b18-prm-20-129]), thoracic ([@b7-prm-20-129]) or spinal surgeries ([@b2-prm-20-129],[@b19-prm-20-129]--[@b24-prm-20-129]), have used larger doses of morphine to achieve adequate pain relief. Gwirtz et al ([@b25-prm-20-129]) reported high patient satisfaction and a low incidence of side effects and complications in \>6000 patients who underwent major urological, orthopedic, general/vascular, thoracic and nonobstetrical gynecological surgery.

While several studies addressing ITM use following spine surgery have been published, they have involved the pediatric population ([@b3-prm-20-129],[@b22-prm-20-129],[@b24-prm-20-129],[@b26-prm-20-129],[@b27-prm-20-129]), used mid- to high-dose ITM ([@b19-prm-20-129],[@b20-prm-20-129],[@b22-prm-20-129],[@b23-prm-20-129],[@b26-prm-20-129],[@b27-prm-20-129]), had no placebo control group ([@b21-prm-20-129]), used as-needed parenteral narcotics ([@b1-prm-20-129]) or used piritramide patient-controlled analgesia (PCA) ([@b2-prm-20-129]) for the control group.

The primary aim of the present study was to determine whether administration of low-dose ITM is a useful adjunct to PCA for providing postoperative pain control following elective lumbar spine surgery in the adult population. The secondary goals were to determine whether ITM affected hospital length of stay, time to ambulation and occurrences of respiratory depression.

METHODS
=======

Patients undergoing elective lumbar laminectomy performed by a single surgeon, with or without fusion, and with or without instrumentation, were considered for entry into the study. Inclusion criteria were signed informed consent and age \>16 years and \<70 years. Exclusion criteria were pregnancy, allergy/intolerance to any of the study medications, chronic morphine use, history of sleep apnea and inability to use PCA.

Intraoperatively, patients all received intravenous fentanyl 1 μg/kg to 3 μg/kg, intravenous sodium thiopental 3 mg/kg to 5 mg/kg and neuromuscular relaxant, at the discretion of the anesthesiologist; per rectum acetaminophen 1300 mg postinduction; maintenance of anesthesia with 60% to 70% nitrous oxide and isoflurane at 0.02% to 1.0% end-tidal concentration; and additional intravenous fentanyl (up to 8 μg/kg) at the discretion of the anesthesiologist.

Research ethics board approval was obtained. Thirty-two consecutive consenting adult patients with American Society of Anesthesiologists health status classifications I, II or III admitted for elective lumbar spinal decompression with or without spinal fusion over a 46-month period were included. Intraoperatively, the patients were randomly assigned to either receive the ITM or intrathecal placebo (ITP). At the conclusion of the operative procedure and before closure, the surgeon administered an identical solution prepared by the pharmacy of either 3.5 μg/kg to a maximum of 350 μg of preservative-free morphine (ITM group) or a placebo consisting of an equivalent volume of preservative-free isotonic saline (ITP group) into the intrathecal space under direct visualization using a 30-gauge needle with the bevel perpendicular to the dura. Less than 5 μg/kg is considered to be a low dose ([@b3-prm-20-129],[@b27-prm-20-129]); thus, 3.5 μg/kg ITM was used with morphine PCA, with the hypothesis that the former would limit the risk of respiratory depression and the latter would provide the option for supplemental morphine and optimize pain control for patients undergoing lumbar spine surgery. On wound closure, all patients received 10 mL of 0.25% bupivicaine with 1:200,000 epinephrine in the subcutaneous tissue surrounding the skin incision, intravenous ondansetron 4 mg before emergence and reversal of neuromuscular blockade at the discretion of the attending anesthesiologist. Both the surgeon and the anesthesiologist were blinded to the study group allocation.

Postoperatively, all patients were given a PCA pump with initial programming consisting of morphine 2.5 mg/mL, bolus of 0.02 mg/kg (maximum 2.0 mg) and lockout of 5 min, with no background infusion. They all received per rectum acetaminophen 1300 mg every 8 h while nil per os or oral acetaminophen 650 mg every 4 h while awake, intravenous/intramuscular dimenhydrinate 25 mg every 4 h as needed. Subsequent management of the PCA pump was at the discretion of the acute pain management anesthesiologist, who was blinded to patient allocation, with the proviso that background infusions were not to be used.

All patients were monitored for the first 18 h to 24 h postoperatively in a step-down unit with continuous oxygen saturation monitoring. The postoperative outcome measures that were evaluated and recorded were: pain intensity, graded by the patient from 1 to 10; total PCA morphine used in the first 24 h postoperatively, measured in milligrams; time to first ambulation, measured in minutes; length of hospital stay, measured in days; nausea intensity, graded by the patient from 1 to 4; pruritis intensity, graded by the patient from 1 to 4; and episodes of respiratory depression (rate \<9 breaths/min).

Statistical analysis was performed using a series of independent-samples *t* tests to compare the two groups with regard to all of the various outcomes. With this sample size, P\<0.05 was considered to be statistically significant. While there are three temporal measures for each patient, repeated-measures ANOVA was not performed because within-person change over time was not of interest; rather, the between-group differences at each point in time were the focus of the analysis. No a priori adjustments were made for multiple comparisons; rather, all P values and sample sizes are presented to enable the reader to interpret the data in the context of the comparisons.

RESULTS
=======

The ITM group included 18 patients and the ITP group included 14 patients. The groups were not significantly different according to patient age, sex, American Society of Anesthesiologists classification and whether a fusion was performed in addition to the lumbar decompression ([Table 1](#t1-prm-20-129){ref-type="table"}).

The average total PCA use over the first postoperative 24 h was significantly less in the ITM group (32.7 mg versus 59.4 mg; P=0.04) ([Table 2](#t2-prm-20-129){ref-type="table"}). There were lower average pain scores in the ITM group at 4 h (P=0.11) and at 8 h (P=0.07) postoperatively; however; this did not attain statistical significance. There was no difference at 24 h postoperatively (P=0.90) ([Figure 1](#f1-prm-20-129){ref-type="fig"}). There were no episodes of respiratory depression experienced by patients in either group.

There was no difference between the groups with regard to nausea at 4 h (P=0.14), 8 h (P=0.23) and 24 h (P=0.56) postoperatively; pruritus at 4 h (P=0.15), 8 h (P=0.32) and 24 h (P=0.91) postoperatively; time to first ambulation (P=0.81); and hospital length of stay (P=0.14) ([Table 2](#t2-prm-20-129){ref-type="table"}).

Sample size calculations were derived on the basis of the cumulative patient-controlled morphine delivered in the first 24 h, as reported by France et al ([@b19-prm-20-129]). SDs were not provided but are estimated on the basis of the magnitude in the current study. Using a mean (± SD) of 7±5.2 and a mean of 25.5±19.1, an alpha of 0.05 and a two-tailed test, the study would have a power of 80% with only 10 patients in each group; this suggests that the current number of 18 and 14 patients would provide adequate power to detect difference in morphine delivery.

The study by France et al ([@b19-prm-20-129]) noted few differences in the complication rates. Itchiness was noted in eight experimental and two control patients; need for nalaxone due to a respiratory rate \<8 breaths/min was demonstrated in three experimental patients and none of the control patients. Neither attained statistical significance. Using an alpha of 0.05 and a power of 80%, 130 patients per group would be required for this to attain statistical significance, suggesting that the current study, as well as the study by France et al ([@b19-prm-20-129]), were both underpowered to detect these complications. However, sample size calculations are not as relevant in the case of relatively rare events and, given that the use of morphine was the primary outcome, the present study had sufficient power for this outcome.

DISCUSSION
==========

Similar to France et al ([@b19-prm-20-129]), we found that the average total PCA use over the first postoperative 24 h was significantly lower in the ITM group, although we used a low dose rather than the mid-range dose that France et al ([@b19-prm-20-129]) used. Therefore, low-dose ITM is an effective early adjunct to PCA in decreasing the amount of self-administered systemic morphine in patients undergoing lumbar spine surgery.

The average pain scores in the ITM group were lower for the first 8 h postoperatively; however, this did not attain statistical significance.

There were no episodes of respiratory depression experienced by patients in the ITM with PCA group. Therefore, although the present study had a small sample size, our data support clinicians who believe that respiratory depression is dose dependent and advocate using low-dose ITM.

There were no differences in measured nausea and pruritus between the ITM and ITP groups. Interestingly, therefore, decreasing the amount of systemic morphine using ITM did not result in less nausea or pruritis in our patients.

We found no difference in time to ambulation or length of stay with the use of ITM. We believe this may be because time to ambulation and length of stay after spine surgery is determined not by postoperative pain but by multiple factors such as preoperative deconditioning, postoperative fatigability and the patients' home support system. Therefore, in the present study, ITM was not a useful adjunct for decreasing hospital resource utilization in lumbar spine surgery.

The strength of our study was in its design methodology. The weakness is the small sample size, which may have reduced our ability to find a statistically significant difference in pain scores in favour of ITM.

CONCLUSION
==========

ITM was an effective adjunct to PCA for decreasing the amount of self-administered systemic morphine required by patients undergoing lumbar spine surgery. Further studies, including larger sample sizes, are needed to show that a low dose provides superior early postoperative pain relief compared with PCA alone, with less respiratory depression than mid-range doses of ITM.
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###### 

Demographic characteristics of participants

  **Characteristic**                                                                                       **ITM**   **ITP**   **P^[\*](#tfn1-prm-20-129){ref-type="table-fn"}^**
  -------------------------------------------------------------------------------------------------------- --------- --------- ----------------------------------------------------
  Sex, female/male, n/n                                                                                    7/11      3/11      0.29
  Age, years, mean                                                                                         54.6      54.8      0.96
  American Society of Anesthesiologists classification, mean^[†](#tfn2-prm-20-129){ref-type="table-fn"}^   2.1       2.3       0.69
  Fusion, n                                                                                                6         3         0.46

*Calculated using χ^2^ tests or two-tailed* t *tests as appropriate;*

Range 1--3. ITM Intrathecal morphine; ITP Intrathecal placebo

###### 

Independent-samples tests for group statistics

                                                                   **Time postoperatively, h**   **Group**   **P[^\*^](#tfn4-prm-20-129){ref-type="table-fn"}**   
  ---------------------------------------------------------------- ----------------------------- ----------- ---------------------------------------------------- ------
  Total 24 h patient-controlled analgesia, mg                                                    32.7        59.4                                                 0.04
  Nausea intensity^[†](#tfn5-prm-20-129){ref-type="table-fn"}^     4                             1.4         1.1                                                  0.14
  8                                                                1.3                           1.1         0.23                                                 
  24                                                               1.4                           1.2         0.56                                                 
  Pruritus intensity^[†](#tfn5-prm-20-129){ref-type="table-fn"}^   4                             1.5         1.1                                                  0.15
  8                                                                1.7                           1.4         0.32                                                 
  24                                                               1.5                           1.5         0.91                                                 
  Time to ambulation, min                                                                        1853        1705                                                 0.81
  Hospital length of stay, days                                                                  4.7         3.6                                                  0.14

Data presented as mean unless otherwise indicated.

*According to two-tailed* t *test;*

On a scale of 1 to 4
